Deinobiotics reports novel antibiotics cla...Researchers at French antibiotics specialist Deinobiotics SAS, a subsidiary of Deinove SA, and German researchers announces the discovery of a new class of resistance breaking antibiotics that kill MRSA … more ➔
EPO under pressure not to lower quality st...Following a letter of about 1,000 EPO patent examiners , also patent attorneys have send an open letter to the European Patent Office (EPO), criticising its outgoing president for having established … more ➔
Adrenomed reveals MOA of sepsis antibodyAdrenomed AG announced the publication of three scientific papers revealing how its adrenomedullin-targeting Phase II sepsis antibody Adrecizumab reverses vascular hyperpermeability in sepsis. more ➔
AMR: FDA provides financing model for nove...As first regulatory body in the world, the FDA has presented a market-driven reimbursement mechanism for antibiotics that may incentivise drug development in a niche market with currently low return … more ➔
Targovax refocussing clinical pipeline pos...Despite a 6-month improvement of 2-year-overall survival in pancreatic cancer patients, Norwegian cancer immunotherapy specialist Targovax ASA will terminate development of TG01 in this indication. … more ➔
Autolus Therapeutics aiming for NASDAQ IPOBritish T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus … more ➔
EC earmarks €100bn for Horizon EuropeEU Commissioners Jyrki Katainen and Carlos Moedas proposed a budget increase of 25% for the next European Research and Innovation programme Horizon Europe (2021-27) vs Horizon 2020. However MEPs … more ➔
MS: Alkermes bags US$50m milestone from Bi...Alkermes plc (Dublin) received a US$50m milestone payment from Biogen after review of preliminary Phase III gastrointestinal tolerability data of Alkermes relapsing-remitting multiple sclerosis candidate diroximel … more ➔
Hookipa and Gilead ink US$400m dealAustrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise … more ➔
Roche set to extend Hemlibra labelThe US FDA has accepted a supplemental BLA to Roche’s existing market approval of the new hemophilia A treatment Hemlibra (emicizumab), which could significantly extend the patient group covered by the … more ➔
